RhumbLine Advisers
LRMR icon

RhumbLine Advisers’s Larimar Therapeutics LRMR Stock Holding History

RhumbLine Advisers’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Buy
71,888
+9,203
+15% +$36.5K ﹤0.01% 3238
2026
Q1 		$282K Sell
62,685
-880
-1% -$3.52K ﹤0.01% 2938
2025
Q4 		$242K Sell
63,565
-5,306
-8% -$20.6K ﹤0.01% 3087
2025
Q3 		$222K Buy
68,871
+1,513
+2% +$5.67K ﹤0.01% 3169
2025
Q2 		$195K Buy
67,358
+2,340
+4% +$5.42K ﹤0.01% 3244
2025
Q1 		$140K Buy
65,018
+8,818
+16% +$27.9K ﹤0.01% 3282
2024
Q4 		$217K Buy
56,200
+519
+0.9% +$3.43K ﹤0.01% 3148
2024
Q3 		$365K Buy
55,681
+745
+1% +$5.99K ﹤0.01% 2916
2024
Q2 		$398K Buy
54,936
+23,475
+75% +$180K ﹤0.01% 2831
2024
Q1 		$239K Buy
31,461
+3,139
+11% +$24.5K ﹤0.01% 3090
2023
Q4 		$129K Sell
28,322
-614
-2% -$2.07K ﹤0.01% 3363
2023
Q3 		$114K Buy
28,936
+2,432
+9% +$9.2K ﹤0.01% 3420
2023
Q2 		$83K Buy
+26,504
New +$108K ﹤0.01% 3569
2019
Q2 		– Sell
-3,226
Closed -$106K – 2995
2019
Q1 		$106K Sell
3,226
-57
-2% -$2.92K ﹤0.01% 2851
2018
Q4 		$195K Buy
3,283
+1,314
+67% +$130K ﹤0.01% 2741
2018
Q3 		$276K Buy
1,969
+225
+13% +$27.3K ﹤0.01% 2557
2018
Q2 		$214K Buy
+1,744
New +$148K ﹤0.01% 2703
2017
Q2 		– Sell
-2,325
Closed -$130K – 2942
2017
Q1 		$130K Buy
2,325
+551
+31% +$27.4K ﹤0.01% 2747
2016
Q4 		$68K Sell
1,774
-1,142
-39% -$46.3K ﹤0.01% 2814
2016
Q3 		$116K Buy
2,916
+25
+0.9% +$1.14K ﹤0.01% 2795
2016
Q2 		$208K Buy
2,891
+1,467
+103% +$116K ﹤0.01% 2721
2016
Q1 		$114K Hold
1,424
– – ﹤0.01% 2870
2015
Q4 		$107K Buy
1,424
+208
+17% +$33.4K ﹤0.01% 2944
2015
Q3 		$466K Buy
1,216
+56
+5% +$25.2K ﹤0.01% 2272
2015
Q2 		$482K Buy
1,160
+682
+143% +$285K ﹤0.01% 2357
2015
Q1 		$227K Buy
+478
New +$227K ﹤0.01% 2768

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

RhumbLine Advisers's LRMR Position: Q2 2026 in Review

RhumbLine Advisers increased its Larimar Therapeutics (LRMR) stake by 15% in Q2 2026, buying an estimated $36.5K and bringing the position to 71,888 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #3238.

RhumbLine Advisers first reported a position in LRMR in Q1 2015 and has held it in 26 quarters since. The position peaked at $482K in Q2 2015. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • RhumbLine Advisers held 71,888 shares of Larimar Therapeutics worth $219K as of Q2 2026.
  • RhumbLine Advisers bought 9,203 Larimar Therapeutics shares in Q2 2026, an estimated $36.5K.
  • Larimar Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3238 holding.
  • RhumbLine Advisers first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 26 quarters since.
  • RhumbLine Advisers's Larimar Therapeutics position peaked at $482K in Q2 2015.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.